Molecularly targeted therapy in hepatocellular carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, frequently diagnosed at advanced stages.
• Advanced HCC exhibits resistance to conventional therapies, necessitating novel treatment strategies.
• Understanding molecular mechanisms has identified receptor tyrosine kinase-activated pathways as key targets.

Purpose of the Study:

• To review evolving molecularly targeted agents for HCC treatment.
• To discuss common adverse effects and potential applications of these agents.
• To highlight strategies for successful future development of targeted therapies.

Main Methods:

• Literature review of molecularly targeted agents in HCC.
• Analysis of clinical trial data for targeted therapies.
• Discussion of molecular targets including Raf/MEK/ERK, PI-3K/Akt/mTOR, and Jak/Stat pathways.

Main Results:

• Sorafenib demonstrated modest survival benefits in advanced HCC, validating targeted therapy approaches.
• Numerous tyrosine kinase inhibitors and monoclonal antibodies are under investigation.
• Future success depends on patient selection, dose optimization, and combination therapies.

Conclusions:

• Molecularly targeted agents represent a promising frontier in advanced HCC management.
• Continued research into patient stratification and combination strategies is crucial.
• These novel therapies offer potential for improved survival and quality of life in HCC patients.